Pharma Blog Watch

BMS CEO Departure (Pharma Marketing Blog)
In his blog, John Mack ponders the ousting of Bristol-Myers Squibb (BMS) CEO Peter Dolan, which according to The Wall Street Journal was due to pressure from a federal monitor. Mack believes Dolan's handling of Plavix and the company's loss of 60 percent of its stock value since he became CEO also influenced BMS' board.

Innogenetics' Suit Against Abbott (Patent Baristas)
In his entry, blogger Stephan Albainy-Jenei discusses a recent ruling that found Abbott Laboratories willfully infringed on Innogenetics' patent covering a method of genotyping hepatitis C. A willful infringement ruling depends, in part, on a company's knowledge of another company's patent, he writes, adding that "once a party has actual notice of another's patent right, that party has an affirmative duty to respect those rights…"